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Abstract Papillary urothelial neoplasms with deceptively
bland cytology cannot be easily classified. We aimed to
design a new algorithm that could differentiate between
these neoplasms based on a scoring system. We proposed a
new scoring system that enables to reproducibly diagnose
non-invasive papillary urothelial tumors. In this system,
each lesion was given individual scores from 0 to 3 for
mitosis and cellular thickness, from 0 to 2 for cellular
atypia, and an additional score for papillary fusion. These
scores were combined to form a summed score allowing the
tumors to be ranked as follows: 0–1 = UP, 2–4 = low
malignant potential (LMP), 5–7 = low-grade transitional
cell carcinoma (TCC), and 8–9 = high-grade TCC. In
addition to the scoring system, ancillary studies of MIB and
p53 indexes with CK20 expression pattern analyses were
compared together with clinical parameters. The MIB index
was strongly correlated with disease progression. Four of
the 22 LMP patients (18.2%) had late recurrences, two of
these four (9.1%) had progression to low-grade carcinoma.
The MIB index for LMP patients was strongly associated
with recurrence (recurrence vs. non-recurrence, 16.5 vs.
8.1, p<0.001). The proposed scoring system could
enhance the reproducibility to distinguish papillary urothe-
lial neoplasms.
Keywords Papillary urothelial neoplasm of lowmalignant
potential . Recurrence .MIB
Introduction
According to the 1998 World Health Organization/Interna-
tional Society of Urological Pathology (WHO/ISUP) [7, 23],
the 1999 WHO blue book [15], and 2004 WHO blue book
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[12], papillary urothelial neoplasms (PUNs) have been
categorized as urothelial papilloma (UP), inverted papilloma
(IP), papillary urothelial neoplasm of low malignant potential
(PUNLMP), low-grade papillary urothelial carcinoma
(LGPUC), and high-grade papillary urothelial carcinoma
(HGPUC). The main aim of the 1998 WHO/ISUP classifi-
cation guidelines was to develop a universally accepted and
reproducible classification system. However, the reproduc-
ible classification and diagnostic criteria between non-
invasive superficial PUN, a constellation of well-known
papillary tumors of low progression incidence, remains in
dispute. In particular, PUNLMP terminology has been the
main point of discussion in the field since the introduction of
the 1998 WHO/ISUP classification system.
UP or IP, whether exophytic or inverted, is well defined
because it usually presents as a small single mass. PUNLMP
is defined as papillary urothelial tumors which resemble
exophytic UP, except for an increased cellular proliferation
that exceeds a normal thickness [7, 12, 15, 23]. LGPUC is
defined as complex papillary fronds with easily recognizable
architectural and cytological variations. Tumors with mod-
erate-to-marked atypia are defined as HGPUC [7, 12, 15,
23]. However, from the pathologic viewpoint, the diagnostic
boundary between stage 0 (Ta) LGPUC and the non-
carcinoma group is vague. By definition, the critical point
for deciphering between PUNLMP and UP is the identifica-
tion of layers exceeding an accepted urothelial thickness.
This step can be very subjective and confusing, which regard
to the section axes [6]. Moreover, architectural and cytologic
atypia favor a LGPUC classification over PUNLMP or UP
classification and are even less reproducible. Through survey
of a consensus trial of papillary urothelial tumors, a severe
discrepancy was observed in PUNLMP by even the most
experienced urologic pathologists [16, 23]. Thus, the clinical
significances and biological differences in PUNLMP are still
inconclusive due to ambiguous diagnostic criteria [5, 17–19].
We designed an algorithm based on the scoring system
defined by several histopathological findings. For confirma-
tion, we surveyed the clinical manifestation and recent 5-year
follow-up data on 175 papillary urothelial tumors. In addition,
we also assessed ancillary studies of MIB and p53 indexes
with CK20 expression pattern analysis. While both ends of
the MIB and p53 index spectrums were easily categorized as
UP and LGPUC, cases within the shaded zone were reviewed
clinically and re-assessed by our scoring system.
Materials and methods
Materials
One hundred seventy-five cases were selected from the
medical records and archival slides. These cases were
selected from a large collection of papillary urothelial
tumors in Urologic Oncology Files of Yonsei University
College of Medicine since 1990.
Demographic data with regard to age, sex, the site
involved, tumor number, size, time to recurrence, frequency
of recurrence, progression, associated malignancy, and
survival time were obtained from each patient’s medical
records. The time of recurrence was calculated from the
time from a complete response (no evidence of disease) to
the time of the first evidence of tumor recurrence at the
latest follow-up. All patients underwent transurethral
resection (TUR) of the bladder tumor. After the initial
TUR was performed at 6-month interval for 2 years and
yearly thereafter, patients did not receive any additional
intravesical treatment until the first recurrence.
All cases were independently reanalyzed by seven
pathologists specialized in urological pathology, in the first
round of the consensus review. Each participant rendered a
diagnosis after a prior training session based on the 2004
WHO classification. After completing the first round, all
cases were reviewed with our new scoring system by all
participants of the present study.
Scoring system
Well-known parameters used in different point systems
were adopted for the new scoring scheme. The most
critical, highly reproducible findings including thickness
of layers and mitosis with cytologic atypia were depicted in
Fig. 1. According to consensus rate between peer
reviewers, relevant impact was given differently. Three
points were given in the best reproducible criteria, thickness
of layers and mitosis, and cytologic atypia. One point was
given in the parameter with wide range of variation,
papillae fusion.
Because increased cellular proliferation exceeding to
seven layers is the minimal criteria for a score, indicating a
more progressive disease than PUNLMP, this particular
criteria should be emphasized. Our general rule was to
judge areas of the section where the papillae are sectioned
perpendicular to the surface and basement membrane and
thus include the central fibrovascular stalk while avoiding
areas of oblique or longitudinally cut. However, despite
unequivocal LGPUC, the loss of umbrella cells leads to a
section that is thinner than seven layers. The scoring criteria
for cellular thickness in the sample was as follows: 0 point
if all fronds had less than seven layers and intact umbrella
cells were present, 1 point if any fronds had less than seven
layers but no obvious umbrella cells were present, 2 points
if samples had more than one frond with more than seven
layers and intact umbrella cells, and 3 points if any fronds
had more than seven layers and no umbrella cells were
present (Fig. 1a).
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Mitotic figures were assessed by recording the total
numbers from ten high power (×400) fields (HPF) selected
at random in each case (Fig. 1b). If more than ten mitoses/
ten HPF were identified, 3 points were given. In case
between five and ten mitosis/ten HPF, 2 points were given.
In case with mitotic index less than 5/10 HPF, 1 point was
given. Samples that did not show any mitosis were given a
0 score.
Although cellular atypia can be another parameter that
can distinguish benign or malignant tumors, caution should
be taken when interpreting this criterion because the
cellular distribution for this characteristic is variable. If
the cellular atypia is restricted to superficial cells, this is
less significant with regard to determining whether a
sample is benign or malignant (Fig. 2). In our scoring
system, samples with randomly and frequently distributed
cellular atypia with moderate to severe degree were given 2
points. One point was assigned to samples with randomly
distributed mild atypia. Samples with no pleomorphism
were given 0 scores (Fig. 1c). The moderate to severe
atypia are defined to be easily recognized in low power
field, whereas mild atypia is observed as slightly variable
nuclear size and clumping of chromatin in high power field.
Cell morphology could be another additive feature that can
distinguish benign and malignant tumors, but not included
in this category. Spindle cells frequently appear in the
benign cases with a gradual transition to epithelioid cells
occasionally as the tumor progresses.
Another mechanism for distinguishing papillary urothe-
lial tumors is by assessing architectural atypia. Because
papillary fusion and branching is an easily recognized and
fairly reproducible finding, a maximum of 1 point was
given when this characteristic was observed. Unequivocal
papillary fusion was given 1 point, and no branching or
fused papillae was given 0 point. Although the palisading
basal layer is another clue to polarity preservation, it is not
definitely diagnostic. However, we experienced this feature
as a strong supportive finding with approaching to the
specific diagnosis of PUNLMP.
The entire scoring system is summarized in Table 1.
Seemingly clear, a diagnostic conundrum occasionally
occurs when a sample falls in the boundary zone. In such
Fig. 1 Histopathological findings of papillary urothelial tumors. a
Thickness of layers. Each number represents the corresponding score:
0 means a thickness less than seven layers with intact umbrella cells, 1
means a thickness less than seven layers with the loss of umbrella
cells, 2 means a thickness more than seven layers with intact umbrella
cells, and 3 means a thickness more than seven layers with the loss of
umbrella cells. b Mitosis. 1 means a few mitoses less than five per
high power field, 2 means mitotic index between five and ten mitoses
per ten HPF, and 3 means more than ten mitoses per ten HPF. c
Cytologic atypia. 0 Atypia restricted to the surface is not considered
true atypia. 1 Diffuse cellular atypia in a random fashion, but with a
mild degree is score 1. 2 Diffuse cellular atypia in a random fashion
and a moderate to severe degree of atypia is defined score 2
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cases, diagnostic ancillary studies can be adopted for
further clarification.
Immunohistochemical analysis
Three consecutive serial sections from each case were
immunostained for MIB, p53, and CK20. In brief, the
4-μm-thick sections of paraffin-embedded tissue were
deparaffinized and rehydrated. After a treatment with a 3%
hydrogen peroxide solution for 10 min to block endogenous
peroxidases, the sections were boiled in 10 mmol/L citrate
buffer (pH 6.0) in a microwave oven for 20 min. The
sections were subsequently incubated at 4°C overnight with
the aforementioned primary antibodies. After a thorough
rinsing in phosphate-buffered saline, the sections were
treated with the DAKO LSAB (labeled streptavidin–biotin)
kit, stained with amino-ethyl carbazole and then counter-
stained with Mayer’s hematoxylin.
Quantitative method
The immunohistochemical staining results were assessed
by a quantitative immunoreactivity score [(ratio of
stained urothelial cells per the total number of tumor
cells)×100]. The MIB index was interpreted by counting
the number of MIB-positive cells out of a total of 1,000
epithelial cells in the most staining area under the high
power magnification (×400). The p53 index was scored
by the ratio derived from the number of p53-positive
cells out of a total of 1,000 epithelial cells. This ratio
was then semi-quantitatively reassorted as 0, 1 (<15%),
and 2 (>15%). CK20 focally stained the surface cells in
normal urothelium. Whereas this focal and patch staining
pattern restrictive to the surface (periphery) was consid-
ered negative in our study, we defined CK20 staining as
positive only when CK20 antibodies diffusely stained
through the entire epithelium. Cells with nuclear MIB
Table 1 Diagnostic scoring system for papillary urothelial tumors
Variables Features Score
Mitosis No mitosis 0
<5/10 HPF 1
5–10/10 HPF 2
>10/10 HPF 3
Thickness of layers <7, with intact umbrella cells 0
<7, with the loss of umbrella cell 1
>7, with intact umbrella cells 2
>7, with the loss of umbrella cell 3
Cytologic atypia None 0
Diffuse mild atypia 1
Diffuse moderate–severe atypia 2
Papillae fusion No 0
Yes 1
Fig. 2 Atypia in surface cells of urothelial papilloma or inverted
papilloma. a Polypoid mass with an inverted pattern of urothelial
nests. b Atypia (asterisk) is noted in the surface (circle) of the inverted
nest. c Atypical cells are not immunoreactive to MIB. d Syncytial
changes of atypical cells (asterisk) are restricted to the surface (circle).
e MIB is scattered, but not expressed in the atypical cells (asterisk) of
the surface (circle)
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and p53 staining as well as cytoplasmic and membra-
nous CK20 staining were regarded as positive cells. The
immunohistochemical staining results were analyzed by
two independent investigators.
Recurrence and progression in long-term follow-up
Individual follow-up times were calculated as the number
of months from the date of the diagnostic surgical
procedure, which was usually a transurethral resection of
the bladder, to the date of the most recent cystoscopy. The
length of the follow-up for the whole series ranged from 15
to 195 months (median, 127 months). A recurrence was
defined as a tumor which was fulgurated (no histopatho-
logical material) or resected (confirmed to be malignant by
histological examination). Stage progression was defined as
a recurrence with a lamina propria invasion (pT1) or the
development of metastatic disease.
Statistical analysis
Statistical analysis was carried out using SPSS (Windows
version 10.0). A Student’s t test was used to evaluate the
associations among the continuous variables. The correlation
between immunoreactive variables was analyzed using the
Pearson correlation study, and frequency distributions were
generated using descriptive statistics (analysis of variance). p
<0.05 was considered to be statistically significant. Associ-
ations between histological categories and immunoreactiv-
ities as well as with tumor recurrence or progression were
assessed by a Chi test. The inter-observer agreement (kappa)
was measured for each diagnostic category as well as for
each score component. The kappa value was interpreted as
follows: 0–0.2, slight; 0.21–0.4, fair; 0.41–0.6, moderate;
0.61–0.8, substantial; and 0.81–1.0, almost perfect.
Results
In the first round, seven pathologists unanimously agreed
on the overall diagnosis in 97 of the 175 subjects (55.4%).
The lowest consensus rate between the pathologists was in
classifying the PUNLMP (27.3%), and the highest consen-
sus rate was in classifying the HGPUC (92.85%). The
overall inter-observer agreement in the first round was
moderate (kappa = 0.587). After the completion of the first
round, all cases were reviewed by all study participants, and
a consensus diagnosis was reached. This consensus
diagnosis was used as the introduction for a newly designed
scoring system combined with ancillary tools mainly based
on the MIB index and clinical factors.
The scoring system, as shown in Tables 1 and 2, consists
of six separately graded components, the scores for which
were then added to determine the total score equivalent to a
diagnostic category. This scoring system was significantly
improved with the adoption of the new scoring scheme in the
second round (kappa = 0.832). The inter-observer agreement
on separate components of this scoring system showed a
substantially increased the classification to a perfect level of
agreement: a kappa of 0.754 for mitosis (substantial
agreement), a kappa of 0.635 for cellular thickness (substan-
tial), and a kappa of 0.556 for cellular atypia (moderate
agreement). With specific regards to PUNLMP, the result of
which had the least consensus, the inter-observer agreement
was substantially improved (kappa = 0.670). The most
consistent findings in low magnification of PUNLMP were
long and slender papillae with partly fused and branched
papillae, and no obvious cytologic atypia (Fig. 3). Basal
palisading features in each papilla can be accounted for the
PUNLMP (Fig. 3c,d). It should be pointed that thickness
more than seven layers with loss of surface cells in any
papillae should never be seen in PUNLMP. The best
diagnostic reproducibility for PUNLMP was mitosis. Ran-
domly scattered mitosis was the most important finding
against the diagnosis of PUNLMP.
Clinicopathological classification of PUN
The mean patient age at the first diagnosis of UP,
PUNLMP, PULC, and PUHC was 62.6, 68.4, 67.1, and
69.3 years, respectively. The following clinical parameters
were included: single vs. multiple, small (less than 1–2 cm)
Table 2 Total score ranges in papillary urothelial tumors
Dx Mitosis Thickness of layers Atypia Fused papilla Total score
UP 0–1 0 0 0 0–1
IP 0–1 0–1 0–1 1 1–3
PUNLMP 0–1 1–2 0 1 2–4
LGPUC 2 1–3 1 1 5–7
HGPUC 3 2–3 2 1 8–9
Atypia means hyperchromacia, irregular nuclear contours and prominent nucleoli.
UP Urothelial papilloma, IP inverted papilloma, PUNLMP papillary urothelial neoplasm low malignant potential, LGPUC low-grade papillary
urothelial carcinoma, HGPUC high-grade papillary urothelial carcinoma
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vs. large (more than 2 cm), no recurrence vs. recurrence,
and no progression vs. progression. UP was all single and
small, but recurred in one patient (14.3%). No progression
or association with LGPUC was found in any of the UP
cases. IP was predominantly single, but 27.3% (6/22) of the
cases were multiple, and 13.6% (3/22) of the cases were
associated with LGPUC. Three cases of IP associated with
LGPUC were typically benign, which were easily differen-
tiated from inverted urothelial carcinoma. None of the IP
cases progressed to LGPUC. PUNLMP frequently presents
with a single and small lesion. Of the PUNLMP cases,
13.6% (3/22) had two or more lesions, but all of them were
small, which were less than 1 cm. Of the PUNLMP
patients, 18.2% (4/22) had a late recurrence (average
21.5 months) and 9.1% (2/22) progressed to LGPUC (after
5 and 56 months, respectively), but never underwent stage
progression to invade muscle proper. Of the LGPUC
patients, 70.4% (38/54) demonstrated a significantly higher
recurrence frequency and 9.3% (5/54) progressed to higher
stages.
MIB, p53 indices, and cytokeratin 20 expression according
to papillary urothelial tumors
Immunohistochemical results of papillary urothelial tumors
based on new scoring system were summarized in Table 3.
The MIB index was variably expressed and increased
proportionately with disease progression (Fig. 4). The mean
MIB index was 5.85, 8.29, 38.74, and 58.32 in UP, LMP,
LGPUC, and HGPUC (p value<0.001), respectively. The
MIB index was relatively and significantly higher in
recurred PUNLMP than in non-recurrent cases (16.5 vs.
8.1, p<0.001). Atypia in surface cells occasionally seen in
papillomas were not immunoreactive to MIB (Fig. 2c,d,
and e). p53 had variable expression ranges in urothelial
tumors and no significant association with recurrence in
spite of an apparent tendency towards disease progression.
CK20 was diffusely immunoreactive in all layers of some
PUNs, whereas these cells are negative or focally reactive
in the superficial cells of UP and IP cases (Fig. 5).
However, CK20 staining had no significant association
with clinicopathological variables.
Discussion
PUNs are a common characteristic of the indolent nature of
papillary tumors with cytologically banal features. They are
often difficult to define with solid classifying criteria for the
low-grade, non-invasive PUNs, benign papillomas, papil-
lary urothelial neoplasms of low malignant potential
(PUNLMP), and low-grade papillary urothelial carcinomas
(LGPUC). The classification of PUNLMP was initially
introduced to replace the previously designated WHO grade
1 urothelial carcinoma that was defined by the 1998 WHO/
ISUP classification system [7, 23]. Murphy [17] interpreted
some of the 1973 WHO grade 1 tumors as PUNLMP and
some as LGPUC, Bostwick and Mikuz [3] translated the
1973 WHO grade 1, 2, and 3 tumors as PUNLMP, LGPUC,
and HGPUC, respectively. Reuter and Melamed [20]
interpreted the 1973 WHO grade 1 tumors as PUNLMP,
grade 2 as LGPUC or HGPUC, and grade 3 as HGPUC.
Based on the histopathological findings, both architec-
tural atypia and cellular atypia are prime parameters that
Fig. 3 Visualization of
PUNLMP with light microscopy.
a Long- and slender-branched
papillae is a characteristic histo-
logical clue for a diagnosis of
PUNLMP. b Branched papillae
are fused. c Basal palisading
feature is another indicator of
PUNLMP. d Branched fused
papillae with basal palisading
feature are a characteristic fea-
ture of PUNLMP
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include thickness of papillae, fused papillae, cellular
pleomorphism, and mitosis. However, some cases can often
have overlapping findings. In a multi-institutional survey in
the Korean Urologic Pathology Society, PUNs diagnoses
were given little consensus by urologic pathologists, despite
the fixed criteria introduced by the WHO guide. Our
substantial discrepancies in diagnoses are quite similar to
data collected from other institutes [16, 23]. Architectural
atypia, such as a thickness more than seven layers and
fused papillae, are very useful in differentiating benign
from worse lesions, but are sometimes confusing due to
tangential sections. In general, cytological atypia is much
more reproducible than architectural atypia. Cellular atypia
can be recognized only along superficial layers or in a
random distribution, whether mild or severe. We found that
the former lacks ki67 expression, which may represent
degenerative changes, not proliferation. Cytologic atypia
that is restricted to the superficial layer can be found in
urothelial benign tumors [4, 6]. Mitosis can be the most
representative and the highly reproducible variable, when
using the total number of mitoses from ten HPF (×400)
selected at random. The benign category of PUN demon-
strated rare, but regular mitoses near the basal layer of the
urothelium. The loss of umbrella cells, degree of the
nuclear groove preservation, cytologic spindling or epithe-
lioid feature, and palisading basal layers can be another
Table 3 Immunohistochemical results in papillary urothelial tumors
Summing
score
MIB (avg. Nc. index)
cut-off >15%
p53 (no. of strong index,
cut-off >15%)
CK20 (intense /diffuse)
UP (n=7) 0.42±0.01 5.85±0.12 0 2 (28.6%)
IP (n=22) 1.63±2.54 7.63±3.57 5 (22.7%) 7 (n=31.8%)
PUNLMP (n=22) 3.08±1.91 8.29±2.14 7 (31.8%) 10 (n=45.5%)
LGPUC (n=54) 6.28±1.04 38.74±12.25 25 (46.3%) 18 (n=33.3%)
HGPUC (n=70) 8.5±0.5 58.32±3.69 48 (68.6%) 25 (n=35.7%)
Avg. Nc. index Average nuclear index
Fig. 4 MIB index of LGPUC. a
Areas of thick trabeculated pa-
pillae (closed circle) are op-
posed to areas of PUNLMP
(semicircle). b Notice many
scattered MIB indexes in the
portion of thick trabeculae,
which represents LGPUC. c
Little MIB indexes were recog-
nized in areas of PUNLMP
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supportive findings, but excluded in this algorithm, because
these findings appear too subjective and less reproducible.
For instance, the loss of umbrella cells may be caused by a
manipulation or a biopsy procedure. Conversely, well-
preserved umbrella cells can be observed in overt carcino-
ma. Basal palisading features in each papilla can be,
however, useful in PUNLMP or IP, whereas overt epithe-
lioid features instead of spindling can be a supportive
finding to favor carcinoma over PUNLMP or papilloma.
For the purpose of achieving a reproducible diagnosis
for PUN, a scoring method based on pathological param-
eters was recently proposed by the Korean Urologic
Pathology Society. The main principle behind this scoring
system is for each parameter to be scored differently with
different weights of implication. For instance, more
concordant parameters such as mitosis and with thickness
of layers were scored by a three-tiered system. The scoring
of atypia was two tiered, and fused papillae was one tiered.
Each diagnosis can be clearly divided when using this
system. Furthermore, PUNs were well categorized with a
high consensus rate upon the application of this algorithm.
A useful tool under the routine microscopy would be an
algorithm derived from our peer-review data in the form of
flow diagram starting features seen at low power (modest
thickness with focal fused papillae) progressing to medium
power (no obvious atypia) and high power (scanty mitosis)
ending up at a diagnosis of PUNLMP.
The helpful ancillary findings for this new scoring
system were the MIB index and clinical findings of
multiplicity, size, and recurrences. Since the MIB index
has been widely known as an independent prognostic
predictor of recurrence [2, 10, 14], it was introduced to
distinguish between PUNs. Most authors reported that the
MIB index of recurrent predictors and poor prognostic
factors is around 10% of the cut-off level. Using the same
method, the MIB index varies according to the time of
fixation [22]. The MIB index in specimens fixed for 50 h
(over the weekend) was significantly lower than the
overnight-fixed specimens. High p53 and MIB expression
could be significant prognostic factors in the univariate
analysis of bladder cancer [8], while p53 is an independent
factor [21].
CK20 showed diffuse immunoreactivity in all layers of
certain PUNs, while negative or focally reactive in the
superficial cells of UP and IP cases. The diffuse and
strong expression of CK20 was correlated to the tumor
severity. Although highly controversial with regard to
their implication of CK20 expression loss, Harnden et al.
[9] found a decreased CK20 expression to be an
independent (p<0.0001) predictor of tumor recurrence in
papillary tumors. Unlike the findings reported by Alsheikh
et al. [1], our data did not reveal a significant correlation
with tumor recurrence.
Upon our survey of clinicopathological correlations, UP
recurred in 14.3% of the patients, but demonstrated no
progression or association with PULC. IP was associated
with LGPUC in 13.6% of the cases, but never progressed to
LGPUC. PUNLMP showed two or more lesions in 13.6%
Fig. 5 Cytokeratin 20 expres-
sion pattern analysis in PUNs. a
CK20 expression was restricted
to the surface. b Patchy areas of
CK20 immunoreactivity had
spread. c Solid compactum of
positive expression was noted. d
Diffuse CK20 expression was
observed
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of the cases, but all of the lesions were less than 1 cm. Of
patients with PUNLMP, 18.2% demonstrated late recur-
rence (average 21.5 months) and 9.1% of the PUNLMP
cases progressed to LGPUC in either 5 or 56 months. Of
the patients with PULC, 70.4% (38/54) demonstrated a
significantly higher frequency of recurrence and 9.3%
(5/54) of these patients progressed to higher stage. With
regard to the labile nomenclature and diagnostic criteria of
PUNLMP, the biological behavior of PUNLMP remains
controversial.
Jordan et al. [13] concluded in a study of 91 cases with
grade 1 urothelial tumors that low-grade lesions, usually
designated transitional cell carcinoma, grade 1, are benign
and should be called papilloma rather than carcinomas. In
contrast, a study by Cheng et al. [6] of 112 PUNLMP cases
found that those with PUNLMP are at risk of cancer
progression and death from bladder cancer. Thus, it is
prudent not to consider a constellation of low-grade
papillary urothelial neoplasms to be benign. Pich et al.
[18] studied 19 LMP cases and found that PUNLMP had a
relatively high recurrence rate (47.4%) with no progression.
These results were also in accordance with the study of 95
LMP cases by Holmang et al. [11]. We apparently observed
that PUNLMP cases demonstrated late recurrences and
progression with relatively lower frequencies, a finding that
represents LMP. Statistical variations of recurrence and
progression depend on many factors, including follow-up
intervals, a definition of recurrence or progression, and
sample size. However, reaching an accurate diagnosis may
be most important. Therefore, we invented an algorithm by
which a greater number of uniform diagnoses with less
discrepancy can be achieved.
In conclusion, the mitotic index and thickness of layers
with cytologic atypia could be useful and reproducible
parameters for the scoring algorithm to discriminate
between papillary urothelial tumors. Based on the new
scoring algorithm, PUNLMP can be clinicopathologically
listed as an intermediary stage between UP and LGPUC.
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